Copertina

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yash Hegde, Freddy Caldera
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
di: Anupam Kumar Singh, et al.
Pubblicazione: (2026)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
di: Anupam Kumar Singh, et al.
Pubblicazione: (2025)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
di: Luisa Bertin, et al.
Pubblicazione: (2026)

Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity
di: Brigida Barberio, et al.
Pubblicazione: (2026)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
di: Nicholas Clark, et al.
Pubblicazione: (2025)

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply
di: Cristina Rubín de Célix, et al.
Pubblicazione: (2025)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease
di: Cong Dai, et al.
Pubblicazione: (2024)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
di: Liang Jiao, et al.
Pubblicazione: (2026)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients With Inflammatory Bowel Disease
di: Chang Liu, et al.
Pubblicazione: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
di: Isabel Carbery, et al.
Pubblicazione: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
di: A. B. Fons, et al.
Pubblicazione: (2026)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
di: Sanjay K. Murthy
Pubblicazione: (2026)

Letter: From Descriptive Epidemiology to Clinical Imperative—Challenging the Paradigm of Pain and Sedative Use in Inflammatory Bowel Disease
di: DuJiang Yang, et al.
Pubblicazione: (2025)

Letter: Critical Insights on a Nationwide Cohort Study of Inflammatory Bowel Disease, Histological Activity and Fracture Risk
di: Saad Khan, et al.
Pubblicazione: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease
di: Jeli Mendoza, et al.
Pubblicazione: (2024)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
di: Purab Patel, et al.
Pubblicazione: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
di: Tamar Schildkraut, et al.
Pubblicazione: (2024)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
di: Matthew D. Coates, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
di: Marco Vincenzo Lenti, et al.
Pubblicazione: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
di: Agnes Hiu Yan Ho, et al.
Pubblicazione: (2025)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
di: Uma Mahadevan, et al.
Pubblicazione: (2025)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
di: Quinn Goddard, et al.
Pubblicazione: (2025)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
di: Jianhui Zhao, et al.
Pubblicazione: (2024)

Editorial: Updated COVID‐19 Boosters—Tailoring Protection for Patients With IBD
di: James L. Alexander, et al.
Pubblicazione: (2024)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
di: Virginia Solitano, et al.
Pubblicazione: (2024)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
di: Fai Fai Ho, et al.
Pubblicazione: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
di: Stephanie Gold, et al.
Pubblicazione: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
di: Suprabhat Giri, et al.
Pubblicazione: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
di: Bharati Kochar, et al.
Pubblicazione: (2025)

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide
di: Lynna Chen, et al.
Pubblicazione: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
di: Joyce Wing Yan Mak
Pubblicazione: (2025)

Maternal and Perinatal Outcomes in Pregnant Women With Comorbid Inflammatory Bowel Disease and Chronic Liver Disease
di: Jessica D. Lee, et al.
Pubblicazione: (2025)

Meta‐Analysis: Pregnancies With Inflammatory Bowel Disease Complicated by Intrahepatic Cholestasis of Pregnancy
di: Shamim Joudaki, et al.
Pubblicazione: (2025)

Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases
di: Dhruv Ahuja, et al.
Pubblicazione: (2025)

Mild Endoscopic Disease Activity Is Associated With Adverse Outcomes Among Older Adults With Inflammatory Bowel Disease
di: Catherine Z. Tang, et al.
Pubblicazione: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
di: Aurelien Amiot, et al.
Pubblicazione: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2025)

Editorial: Shooting in the Dark—The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease
di: Jane Lim, et al.
Pubblicazione: (2025)